UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 — Santa Monica, California

UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 is a clinical research site located in Santa Monica, California, United States 90095.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 has participated in 1 clinical trials.

Therapeutic areas: Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor.

Sponsors: Akamis Bio.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Santa Monica

Browse all research sites in California · View every site in Santa Monica

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360?

UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 conducted?

UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 has 1 clinical trials on record. Their work covers Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor.

Is UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 accredited by Crixeo Clinical Trials?

UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.